Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Law Office of Brodsky & Smith, LLC Announces Investigation of Somaxon Pharmaceuticals, Inc.



    Law Office of Brodsky & Smith, LLC Announces Investigation of Somaxon
                            Pharmaceuticals, Inc.

PR Newswire

BALA CYNWYD, Pa., Dec. 13, 2012

BALA CYNWYD, Pa., Dec. 13, 2012 /PRNewswire/ -- Law office of Brodsky & Smith,
LLC announces that it is investigating potential claims against the Board of
Directors of Somaxon Pharmaceuticals, Inc. ("Somaxon" or the "Company")
(Nasdaq- SOMX) relating to the proposed acquisition by Pernix Therapeutics
Holdings, Inc. ("Pernix").

Under the terms of the transaction, Somaxon shareholders will receive only $25
million in Pernix common stock. The number of Pernix stock issued will be
based on the volume-weighted average price of Pernix's common stock in the 30
day period prior to the merger closing, representing a value of between $6.00
and $9.00 per Somaxon share. The investigation concerns possible breaches of
fiduciary duty and other violations of state law by the Board of Directors of
Somaxon for not acting in the Company's shareholders' best interests in
connection with the sale process to Pernix.

The transaction may undervalue the Company and will result in a loss for many
shareholders. For example Somaxon stock traded at $27.28 as recently as
January 6, 2011. In addition, in the 12 months ended September 30, 2012,
Somaxon had net sales related to Silenor, a drug approved to treat insomnia,
of approximately $11.7 million.  Silenor has potential to produce additional
revenue as an over-the-counter product in the future.

If you own shares of Somaxon stock and wish to discuss the legal ramifications
of the proposed transaction, or have any questions, you may e-mail or call the
law office of Brodsky & Smith, LLC who will, without obligation or cost to
you, attempt to answer your questions.  You may contact Jason L. Brodsky,
Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza,
Suite 602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com visiting
http://brodsky-smith.com/518-somx-somaxon-pharmaceuticals-inc.html, by calling
toll free 877-LEGAL-90.

SOURCE Brodsky & Smith, LLC

Website: http://www.brodsky-smith.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement